Product Information
RIVELSA TABLET is a generic product labeled by Teva Pharmaceuticals USA Inc., priced at $1.3712 per EA under NDC 00093603182. Its NADAC has been published 100 times since Apr 17, 2024.
FDA first approved this application on Mar 28, 2013. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Manufacturer
Teva Pharmaceuticals USA Inc.NDC
00093603182
Classification
Generic
Dosage Form
KIT
Effective Date
9/23/2026
Approval Type
Authorized Generic (NDA)
FDA Application
NDA204061FDA Approved
3/28/2013
TE Code
AB
On Market Since
4/3/2017
Price Statistics
The NADAC for RIVELSA TABLET has been published 100 times since Apr 17, 2024, and over the history we have for it it has declined 28.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.3712 per EA |
|---|---|
| All-time high | $1.9332 (Dec 11, 2024) |
| All-time low | $1.2238 (Jun 18, 2025) |
| 52-week high | $1.7000 |
| 52-week low | $1.2803 |
| Median price | $1.5961 |
| Average price | $1.5843 |
| Largest weekly change | +32.8% (May 20, 2026) |
| Weeks tracked | 100 |
| Tracking since | Apr 17, 2024 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 83% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Teva Pharmaceuticals USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Levonorgestrel/Ethinyl Estradiol and Ethinyl Estradiol market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of RIVELSA TABLET?
The current National Average Drug Acquisition Cost (NADAC) for RIVELSA TABLET, manufactured by Teva Pharmaceuticals USA Inc., is $1.3712 per EA (NDC 00093603182), effective Sep 30, 2026.
How has the price of RIVELSA TABLET changed over time?
Over the history we have for it, the NADAC for RIVELSA TABLET has declined 28.0%. It has been tracked across 100 weekly CMS publications since Apr 17, 2024.
What are the highest and lowest recorded NADAC prices for RIVELSA TABLET?
Since Apr 17, 2024, the NADAC for RIVELSA TABLET has ranged from a low of $1.2238 (Jun 18, 2025) to a high of $1.9332 (Dec 11, 2024), with a median of $1.5961 per EA.
Are there cheaper alternatives to RIVELSA TABLET?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, CAMRESE LO TABLET, is $0.2339 per EA — about 83% below RIVELSA TABLET.
Who manufactures RIVELSA TABLET?
RIVELSA TABLET (NDC 00093603182) is labeled by Teva Pharmaceuticals USA Inc., and CMS classifies it as a generic product.